Ocean Biomedical Inc. Common Stock OCEA · Stock Open Ocean Biomedical Inc. Common Stock in new tab
Ocean Biomedical Inc. Common Stock Analysis (OCEA)
Is Ocean Biomedical Inc. Common Stock a good investment? Ocean Biomedical Inc. Common Stock (OCEA) is currently trading at 0.000900 USD.
Earnings Schedule: Ocean Biomedical Inc. Common Stock is expected to release its next earnings report on Dec. 2, 2026. The market consensus estimate for Forward EPS is -0.89.
Investor FAQ
Does Ocean Biomedical Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Ocean Biomedical Inc. Common Stock?
Ocean Biomedical Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Dec. 2, 2026. The company currently has a trailing EPS of -0.91.
Company Profile
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS). The company's infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P. falciparum infection; ODA-611 anti-PfGARP mAb for the treatment of Symptomatic P. falciparum infection; and ODA-579 anti-PfGARP small molecule for the treatment of Symptomatic P. falciparum infection. It has license agreement with Elkurt, Inc. for FRG Antibody, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.
Community Discussion